Association between CYP2C19 genotype and proguanil oxidative polymorphism

被引:17
作者
Coller, JK
Somogyi, AA
Bochner, F
机构
[1] Dept. of Clin. and Exp. Pharmacology, University of Adelaide, Adelaide, SA
[2] Dept. of Clin. and Exp. Pharmacology, University of Adelaide, Adelaide
关键词
proguanil; metabolic ratio; intrinsic clearance; CYP2C19; mutant alleles;
D O I
10.1046/j.1365-2125.1997.00596.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To examine the relationship between proguanil metabolism and the number of mutations in CYP2C19 by comparing the CYP2C19 genotype and proguanil phenotype of 10 subjects. Methods Partial clearance and urinary metabolic ratio data were obtained from a previous study of 10 subjects [5]. Analysis of CYP2C19 genotypes was performed using PCR amplification followed by restriction endonuclease digestion of genomic DNA from a blood sample. Results The intrinsic partial clearance of PG to CG ranged from 0.41-10.11 h(-1), and was related to the number of functional CYP2C19 alleles present. Genotypic PMs had metabolic ratios >13, while genotypic heterozygote EMs had metabolic ratios <9. Conclusions Proguanil may be a suitable phenotyping probe for the CYP2C19 genetic polymorphism, however the exact antimode of the urinary metabolic ratio chosen to separate poor and extensive metabolisers needs further investigation.
引用
收藏
页码:659 / 660
页数:2
相关论文
共 10 条
  • [1] IN-VITRO PROGUANIL ACTIVATION TO CYCLOGUANIL BY HUMAN LIVER-MICROSOMES IS MEDIATED BY CYP3A ISOFORMS AS WELL AS BY S-MEPHENYTOIN HYDROXYLASE
    BIRKETT, DJ
    REES, D
    ANDERSSON, T
    GONZALEZ, FJ
    MINERS, JO
    VERONESE, ME
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (05) : 413 - 420
  • [2] Nomenclature for human CYP2D6 alleles
    Daly, AK
    Brockmoller, J
    Broly, F
    Eichelbaum, M
    Evans, WE
    Gonzalez, FJ
    Huang, JD
    Idle, JR
    IngelmanSundberg, M
    Ishizaki, T
    JacqzAigrain, E
    Meyer, UA
    Nebert, DW
    Steen, VM
    Wolf, CR
    Zanger, UM
    [J]. PHARMACOGENETICS, 1996, 6 (03): : 193 - 201
  • [3] DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594
  • [4] DEMORAIS SMF, 1994, J BIOL CHEM, V269, P15419
  • [5] GENETIC-ANALYSIS OF THE S-MEPHENYTOIN POLYMORPHISM IN A CHINESE POPULATION
    DEMORAIS, SMF
    GOLDSTEIN, JA
    XIE, HG
    HUANG, SL
    LU, YQ
    XIA, H
    XIAO, ZS
    ILE, N
    ZHOU, HH
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 58 (04) : 404 - 411
  • [6] OXIDATIVE ACTIVATION OF PROGUANIL AND DAPSONE ACETYLATION IN THAI SOLDIERS
    EDSTEIN, MD
    SHANKS, GD
    TEJAISAVADHARM, P
    RIECKMANN, KH
    WEBSTER, HK
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 37 (01) : 67 - 70
  • [7] THE PHARMACOKINETICS AND ACTIVATION OF PROGUANIL IN MAN - CONSEQUENCES OF VARIABILITY IN DRUG-METABOLISM
    HELSBY, NA
    WARD, SA
    EDWARDS, G
    HOWELLS, RE
    BRECKENRIDGE, AM
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 30 (04) : 593 - 598
  • [8] Pharmacokinetic evaluation of proguanil: A probe phenotyping drug for the mephenytoin hydroxylase polymorphism
    Somogyi, AA
    Reinhard, HA
    Bochner, F
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 41 (03) : 175 - 179
  • [9] INTER-SUBJECT VARIABILITY IN THE METABOLISM OF PROGUANIL TO THE ACTIVE METABOLITE CYCLOGUANIL IN MAN
    WARD, SA
    WATKINS, WM
    MBERU, E
    SAUNDERS, JE
    KOECH, DK
    GILLES, HM
    HOWELLS, RE
    BRECKENRIDGE, AM
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1989, 27 (06) : 781 - 787
  • [10] VARIABILITY IN THE METABOLISM OF PROGUANIL TO THE ACTIVE METABOLITE CYCLOGUANIL IN HEALTHY KENYAN ADULTS
    WATKINS, WM
    MBERU, EK
    NEVILL, CG
    WARD, SA
    BRECKENRIDGE, AM
    KOECH, DK
    [J]. TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1990, 84 (04) : 492 - 495